2,527products in the catalogue
2,367EU-authorised medicines (EMA)
160FDA approvals
5 yrsforecast horizon, 2027–2031
Free report
The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Two ways to buy
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
€1,250 per product
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
€4,950 5 products
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
from €4,500
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
What is in every report
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Catalogue
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Trumenba meningococcal group b vaccine (recombinant, adsorbed) | Pfizer Europe MA EEIG | Meningitis, Meningococcal | 🇪🇺 EU 2017-05-24 | Order → |
| Ivabradine Accord ivabradine Generic | Accord Healthcare S.L.U. | Angina Pectoris; Heart Failure | 🇪🇺 EU 2017-05-22 | Order → |
| Axumin fluciclovine (18F) | Blue Earth Diagnostics Ireland Ltd | Prostatic Neoplasms; Radionuclide Imaging | 🇪🇺 EU 2017-05-21 | Order → |
| Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron) dinutuximab beta OrphanExceptional circumstancesAdditional monitoring | Recordati Netherlands B.V. | Neuroblastoma | 🇪🇺 EU 2017-05-08 | Order → |
| Emtricitabine/Tenofovir disoproxil Krka d.d. emtricitabine;tenofovir disoproxil Generic | KRKA tovarna zdravil d.d. Novo mesto | HIV Infections | 🇪🇺 EU 2017-04-28 | Order → |
| Natpar parathyroid hormone OrphanConditionalAdditional monitoring | Takeda Pharmaceuticals International AG Ireland Branch | Hypoparathyroidism | 🇪🇺 EU 2017-04-24 | Order → |
| Pemetrexed Pfizer (previously Pemetrexed Hospira UK Limited) pemetrexed Generic | Pfizer Europe MA EEIG | Carcinoma, Non-Small-Cell Lung; Mesothelioma | 🇪🇺 EU 2017-04-24 | Order → |
| Roteas edoxaban | Berlin-Chemie AG | Stroke; Venous Thromboembolism | 🇪🇺 EU 2017-04-19 | Order → |
| Varuby rolapitant Additional monitoring | TESARO Bio Netherlands B.V. | Vomiting; Nausea; Cancer | 🇪🇺 EU 2017-04-19 | Order → |
| Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau) chenodeoxycholic acid OrphanExceptional circumstancesAdditional monitoring | Leadiant Biosciences Ireland Limited | Xanthomatosis, Cerebrotendinous; Metabolism, Inborn Errors | 🇪🇺 EU 2017-04-10 | Order → |
| Jylamvo methotrexate | Oresund Pharma ApS | Arthritis, Psoriatic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Psoriasis; Arthritis, Rheumatoid; Arthritis | 🇪🇺 EU 2017-03-29 | Order → |
| Daptomycin Hospira daptomycin Generic | Pfizer Europe MA EEIG | Soft Tissue Infections; Skin Diseases, Bacterial | 🇪🇺 EU 2017-03-22 | Order → |
| Solymbic adalimumab BiosimilarAdditional monitoring | Amgen Europe B.V. | Arthritis, Psoriatic; Spondylitis, Ankylosing; Crohn Disease; Colitis, Ulcerative; Hidradenitis Suppurativa; Psoriasis; Arthritis, Rheumatoid | 🇪🇺 EU 2017-03-22 | Order → |
| Tadalafil Lilly tadalafil | Eli Lilly Nederland B.V. | Erectile Dysfunction | 🇪🇺 EU 2017-03-22 | Order → |
| Xeljanz tofacitinib | Pfizer Europe MA EEIG | Arthritis, Rheumatoid | 🇪🇺 EU 2017-03-22 | Order → |
| Yargesa miglustat Generic | Piramal Critical Care B.V. | Gaucher Disease | 🇪🇺 EU 2017-03-22 | Order → |
| Amgevita adalimumab Biosimilar | Amgen Europe B.V. | Arthritis, Psoriatic; Colitis, Ulcerative; Arthritis, Juvenile Rheumatoid; Spondylitis, Ankylosing; Psoriasis; Crohn Disease; Arthritis, Rheumatoid | 🇪🇺 EU 2017-03-21 | Order → |
| Rolufta Ellipta (previously Rolufta) umeclidinium | GlaxoSmithKline Trading Services Limited | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2017-03-20 | Order → |
| Ledaga chlormethine Orphan | Helsinn Birex Pharmaceuticals Ltd. | Mycosis Fungoides | 🇪🇺 EU 2017-03-03 | Order → |
| Pregabalin Zentiva k.s. pregabalin Generic | Zentiva k.s. | Anxiety Disorders; Neuralgia; Epilepsy | 🇪🇺 EU 2017-02-27 | Order → |
Order
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.